Podcast appearances and mentions of vijay pande

What if we stopped trying to cure disease and started preventing it instead? In this episode, Eric Topol, founder and director of the Scripps Research Translational Institute and a cardiologist, scientist, and author, joins a16z general partner Vijay Pande to unpack the future of aging, prevention, and precision health—as explored in Eric's new book, Super Agers: An Evidence-Based Approach to Longevity.Together, they discuss AI-driven risk prediction and next-gen immunotherapies — a roadmap for how we could eliminate age-related diseases before they begin. From the transformative potential of GLP-1 drugs to organ-specific aging clocks, this episode is about the innovations with the potential to expand healthspan, not just lifespan.Learn more about a16z Bio+HealthLearn more about & Subscribe to Raising HealthFind a16z Bio+Health on LinkedInFind a16z Bio+Health on X

American healthcare is in crisis—but what if we could change the system by preventing disease before it starts?In this episode of the a16z Podcast, general partner Vijay Pande sits down with Dr. Eric Topol, founder and director of the Scripps Research Translational Institute and one of the most cited researchers in medicine, to explore the cutting edge of preventive healthcare and longevity science.Drawing from his new book Super Agers: An Evidence-Based Path to Longevity, Topol breaks down why understanding the biology of aging—not reversing it—is the key to preventing the “Big Three” age-related diseases: cancer, cardiovascular disease, and neurodegenerative conditions. The conversation spans AI-powered risk prediction, organ clocks, polygenic risk scores, GLP-1s, and the cultural and economic shifts required to move from a “sick care” system to one rooted in precision prevention and extended healthspan.If you've ever wondered how data, personalized medicine, and AI can add seven healthy years to your life—and what it will take to bring those benefits to everyone—this episode is for you. Resources: Find Eric on X: https://x.com/erictopolFind Vijay on X: https://x.com/vijaypande Stay Updated: Let us know what you think: https://ratethispodcast.com/a16zFind a16z on Twitter: https://twitter.com/a16zFind a16z on LinkedIn: https://www.linkedin.com/company/a16zSubscribe on your favorite podcast app: https://a16z.simplecast.com/Follow our host: https://twitter.com/stephsmithioPlease note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.

Join a16z general partners Marc Andreessen, Julie Yoo, and Vijay Pande for an incisive exploration of what's driving—and stalling—transformation in healthcare. With the industry now consuming nearly 20% of U.S. GDP yet delivering poor outcomes relative to other developed countries, is technology the remedy or a red herring?This episode, cross-posted with the a16z podcast, dissects the inertia holding healthcare back, from regulatory bottlenecks to misaligned incentives, while offering actionable insights for entrepreneurs navigating this complex space. Plus:Learn more about a16z Bio+HealthLearn more about & Subscribe to Raising HealthFind a16z Bio+Health on LinkedInFind a16z Bio+Health on X

Healthcare is a $4 trillion industry, making up nearly a fifth of the U.S. economy—but despite having some of the best doctors and advanced technology, the system often delivers poor outcomes at skyrocketing costs. Why is this the case, and what will it take to fix it?In this episode, a16z cofounder Marc Andreessen and General Partners Vijay Pande and Julie Yoo tackle some of the biggest questions shaping the future of healthcare:Is the solution to our healthcare crisis a policy, technology, or competition problem?Will AI and technology transform the industry, or are regulatory and structural barriers too entrenched?Who will crack the code—healthcare incumbents, tech giants, or AI-native startups?From chronic care to cost curves, from disruptive technologies to shifting patient agency, this conversation offers an unfiltered look at what's broken in the healthcare system and how it might finally change.Resources: Find Marc on X: https://x.com/pmarcaFind Vijay on X: https://x.com/vijaypandeFind Julie on X: https://x.com/julesyooThe Biggest Company in the WorldWhy Will Healthcare be the Industry that Benefits Most from AI?Grand Challenges in Healthcare AI with Vijay Pande and Julie YooStay Updated: Let us know what you think: https://ratethispodcast.com/a16zFind a16z on Twitter: https://twitter.com/a16zFind a16z on LinkedIn: https://www.linkedin.com/company/a16zSubscribe on your favorite podcast app: https://a16z.simplecast.com/Follow our host: https://twitter.com/stephsmithioPlease note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.

Parag Mallick discusses the role of AI and machine learning in biotech with special guests Vijay Pande from Andreessen Horowitz and Matt McIlwain from Madrona Venture Group. Their fascinating conversation covers:Advances that have enabled biotech to make use of AI and machine learningHow founders are applying AI and machine learning in biotechThe future of AI and machine learning in biotechChapters00:00 - Introduction04:37 - How did Vijay and Matt get into AI and ML07:33 - The importance of structured data, advances in compute, and algorithmic advances in driving the boom in machine learning18:44 - The Intersection of AI and biology21:57 - The evolution of biological models31:55 - The Complexity of biological data39:42 - Ways founders and biotech startups are using AI43:25 - Favorite/Impactful applications of AI/ML47:00 - AI for experimental design50:13 - The future of AI in bio/healthResourcesLearn more about Matt McIlwainLearn more about Vijay PandeFolding at HomeLearn about various types of machine learning on IBM's websiteLearn about autoencoders on IBM's websiteLearn more about transformers on NVIDIA's blogTranslating Proteomics Episode 6 - The Future of AI in Biomedicine

What if the biggest challenge of our time isn't living longer, but living better? In this episode, we're tackling one of humanity's greatest accomplishments—and perhaps its most overlooked challenge: longevity. As more people live past 100, our systems—healthcare, finance, career planning, and even our cultural perceptions of aging—need a fundamental overhaul. We're joined by Dr. Andrew Scott, author of The Longevity Imperative, and Vijay Pande a16z's Bio & Health general partner, to explore how a shift from “sick care” to “health care” could transform our lives. Together, we discuss the implications of longer lifespans, from the individual choices that can improve our healthspans to the economic and societal shifts required to sustain a healthier, more productive aging society. Join us as we reimagine the future of aging, where living to 100 can be more than survival—it can be a life well-lived. Resources: Find Andrew on X: https://x.com/profandrewscott?lang=enFind Vijay on X: https://x.com/vijaypandeLearn more about The Longevity Imperative:https://profandrewjscott.com/the-longevity-imperative/ Stay Updated: Let us know what you think: https://ratethispodcast.com/a16zFind a16z on Twitter: https://twitter.com/a16zFind a16z on LinkedIn: https://www.linkedin.com/company/a16zSubscribe on your favorite podcast app: https://a16z.simplecast.com/Follow our host: https://twitter.com/stephsmithioPlease note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.

In this episode, Vijay Pande and Daisy Wolf of a16z Bio + Health join a16z Podcast host Steph Smith to make a provocative case for why technologists—not just medical professionals—are key to reinventing healthcare. They argue that to transform a sector representing 20% of U.S. GDP, innovation must move beyond curing diseases toward tackling healthcare's broken systems. By likening the healthcare industry to a logistics challenge, Vijay and Daisy outline how technologists can leverage their expertise in consumer engagement, operational efficiency, and AI to drive the next frontier of health innovation. They also explore high-impact opportunities like improving patient experiences and deploying AI for behavioral change at scale. If you're ready to explore new paths in healthcare, this episode is essential listening for understanding the powerful role technologists can play in shaping its future.

Vijay Pande, PhD, founding partner of a16z Bio + Health, joins Derrick Harris, host of the AI + a16z podcast. Together, they discuss how computer science has subsumed biotech.

Vijay Pande, founding general partner, and Julie Yoo, general partner at a16z Bio + Health, come together to discuss the grand challenges facing healthcare AI today.The talk through the implications of AI integration in healthcare workflows, AI as a potential catalyst for value-based care, and the opportunity for innovation in clinical trials. They also talk about the AI startup they each wish would walk through the door.  Resources: Find Vijay on Twitter: https://x.com/vijaypandeFInd Julie on Twitter: https://x.com/julesyooListen to more episode from Raising Health: https://a16z.com/podcasts/raising-health/ Stay Updated: Let us know what you think: https://ratethispodcast.com/a16zFind a16z on Twitter: https://twitter.com/a16zFind a16z on LinkedIn: https://www.linkedin.com/company/a16zSubscribe on your favorite podcast app: https://a16z.simplecast.com/Follow our host: https://twitter.com/stephsmithioPlease note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.

Casey Means, MD, a Stanford-trained physician, cofounder of Levels, and author of the new book Good Energy, joins Vijay Pande,  PhD, founding partner of a16z Bio + Health.Together, they discuss the downsides of physician specialization, the rising tide of chronic illness in the U.S., and how tracking biomarkers might allow people to determine the best nutrition options for their unique physiology. Casey's book is available here.

In this episode of NEJM AI Grand Rounds, hosts Raj Manrai and Andy Beam interview Dr. Vijay Pande, a general partner at Andreessen Horowitz (A16Z) where he leads investments in health care and life sciences. The conversation explores Pande's journey from academia to venture capital, his views on the future of AI in health care and biomedicine, and insights into the investment landscape for biotech and health tech companies. Pande discusses the challenges and opportunities in integrating AI into medical practice, the potential for AI to democratize health care access, and his thoughts on the development of artificial general intelligence (AGI). Transcript.

Bowen Liu, PhD, investing partner, and Surya Ganguli, PhD, venture partner, join Vijay Pande, PhD, general partner of a16z Bio + Health.Together, they detail different methods through which AI could assist drug development, the opportunity for AI to flag new targets and compounds for scientists to investigate, and the science fiction-sounding notion of developing a foundation model that untangles biology.This is an in-depth conversation from three AI experts and biologists, so we'll also publish the transcript alongside the episode on our website if you want to follow along. 

In this episode, a follow-up to our episode Grand Challenges in Healthcare AI, Julie Yoo and Vijay Pande, a16z general partners, answer audience questions about AI applications in healthcare.Together, they dive into cost and implementation challenges, the data landscape, and what the patient experience might look like.If you liked this episode, listen to Grand Challenges in Healthcare AI here or wherever you get your podcasts.

Jonathan Swerdlin, cofounder and CEO, and Mark Hyman, MD, cofounder and Chief Medical Officer of Function Health join Vijay Pande, general partner, and Daisy Wolf, investment partner of a16z Bio + Health.Together, they discuss their personal health journeys that led to founding Function, how they're planning to scale Function, and what the future could look like.

View Show Notes From This Episode Get Free Weekly Health Tips from Dr. Hyman Sign Up for Dr. Hyman's Weekly Longevity Journal AI is set to revolutionize healthcare as we know it - improving diagnostics, treatment personalization, patient care, while simultaneously reducing costs and enhancing outcomes. In this episode of “The Doctor's Farmacy,” I sit down with Vijay Pande, PhD and Daisy Wolf, JD to explore how investors are shaping the future by funding innovative companies that address our system's fundamental problems. Discover how cutting-edge tech, like wearable devices and AI diagnostics, is making personalized medicine more accessible and effective for everyone. This episode is brought to you by Butcher Box, Mitopure, and Wonderfeel. ButcherBox is giving new members two pounds of wild-caught salmon for FREE plus $20 off. Visit ButcherBox.com/Farmacy and use code FARMACY. Support essential mitochondrial health and save 10% on Mitopure. Visit TimelineNutrition.com/Drhyman and use code DRHYMAN10. Wonderfeel Youngr™ NMN works by increasing your levels of NAD, a critical molecule our bodies produce that we literally need to survive. Feel the wonder of innovation at GetWonderfeel.com.

In this episode, originally recorded for the a16z Podcast, host Steph Smith interviews Pushmeet Kohli, DeepMind's VP of Research focused on AI for science. They are joined by a16z Bio + Health founding partner Vijay Pande.Together, they discuss AI at scale, and its power to transform science.

Carolyn Jasik, MD, Chief Medical Officer of Omada Health, joins Vijay Pande, founding partner of a16z Bio + Health.As Ozempic, Wegovy, Mounjaro, and Zepbound capture the healthcare spotlight, we've developed a series of episodes that go beyond the headlines and take you into conversations with the specialists. Our first guest is Carolyn Jasik, Chief Medical Officer at Omada Health. She gives us an overview of the science of satiety, the perspective from obesity-focused physicians, and the sometimes surprising lifestyle implications for patients on these medicines.This series provides insight into what anti-obesity medicines are, where they're going, and the challenges that have to be overcome along the way.

Kim Branson, PhD, SVP and Global Head of AI and Machine Learning for GSK, joins Vijay Pande, founding partner at a16z Bio + Health.Together, they talk about how AI has improved drug discovery and development, as Kim walks through all the ways AI can be deployed in the lab. They also get into detail about what an ideal partner looks like and what kind of solution is attractive to a big biopharma, making this a particularly relevant episode for builders in biotech AI.

Tom Hale, CEO of ŌURA, joins Vijay Pande, founding partner, and Daisy Wolf, investment partner at a16z Bio + Health.Together, they talk about the potential of wearables to change behavior, and how that can affect health. They also discuss how AI could maximize the usefulness of wearables and power the insights provided to wearers.

Philip Tagari, Chief Scientific Officer of insitro, joins Vijay Pande, founding general partner at a16z Bio + Health.Together, they discuss the transformative power of drugs in changing human health—and history. They also reflect on the evolution of the drug discovery process as it shifts from serendipitous discovery to AI-enabled engineering. Finally, they chat about where the industry is headed, and how AI might change the competition landscape.

Vijay Pande, founding general partner of a16z Bio + Health, chats with the builders (and siblings) behind Devoted Health, Ed and Todd Park. The Park brothers, with decades of expertise in healthcare and policy, including as EVP and COO at athenahealth (Ed) and Chief Technology Officer of the United States (Todd),  started Devoted with the idea of building a healthcare model from scratch. Together, their discussion underscores the sector's urgent need for technological innovation and the game-changing role of AI.This episode was recorded live at a16z's LP Summit.

Vijay Pande, founding general partner, and Julie Yoo, general partner at a16z Bio + Health, come together to talk through the grand challenges facing healthcare AI today.The discussion covers the implications of AI integration in healthcare workflows, AI as a potential catalyst for value-based care, and the potential for innovation in clinical trials. They also talk about the AI startup they each wish would walk through the door. 

"There is a revolution unfolding in biotech. The confluence of new biological methods like CRISPR, virtually unlimited computational capacity, and machine learning has fundamentally transformed our ability to engineer biology for wide-ranging applications."Vijay Pande, founding general partner at a16z Bio + Health, joins the Software Engineering Daily podcast to talk about innovation in biotech and healthcare, the biotech startup landscape, the impact of AI, and much more.You can see a transcript of the episode and more information about Software Engineering Daily here.

Vijay Pande, founding partner of a16z Bio + Health, dives deep with a16z Podcast host Steph Smith into the potential of DNA as a data storage mechanism.This episode, a cross-post with the a16z Podcast, draws parallels between Moore's Law and the race for "Moore's Law for DNA." Vijay discusses the density, longevity, and ubiquity of DNA, and how this could be leveraged into a data storage solution. Vijay and Steph mix technical advancements with futuristic speculation as they talk about what the future of biotech might look like.

Scribe Therapeutics cofounder and CEO Benjamin Oakes, PhD, joins a16z Bio + Health founding general partner Vijay Pande.In this episode, Benjamin traces his journey from PhD student to pioneering CEO in genome editing. Benjamin discusses his early exposure to CRISPR technologies, his hands-on experience of transforming these bacterial immune systems into "genome editing scalpels," and the founding of Scribe. The conversation sheds light on the challenges of engineering these molecules, as well as the potential for life-changing therapeutics.

Josh Clemente, cofounder and president of Levels, joins Vijay Pande, founding general partner, and Daisy Wolf, investment partner at a16z Bio + Health.In this episode, engineer-turned-entrepreneur Josh charts his journey from SpaceX and Hyperloop to cofounding metabolic health-focused company Levels. With a relentless drive for data-led health monitoring, Josh highlights the potential of wearable tech for tracking various biomarkers. Josh, Vijay, and Daisy also discuss how AI can simplify complex wearables data into a comprehensible and actionable health profile, with the potential to democratize healthcare technology.

There is a revolution unfolding in biotech. The confluence of new biological methods like CRISPR, virtually unlimited computational capacity, and machine learning has fundamentally transformed our ability to engineer biology for wide-ranging applications. Andreessen Horowitz, or a16z, is a venture capital firm that was founded by Marc Andreessen and Ben Horowitz. Vijay Pande is a The post Biotech Special: a16z and the Biotech Revolution with Vijay Pande appeared first on Software Engineering Daily.

There is a revolution unfolding in biotech. The confluence of new biological methods like CRISPR, virtually unlimited computational capacity, and machine learning has fundamentally transformed our ability to engineer biology for wide-ranging applications. Andreessen Horowitz, or a16z, is a venture capital firm that was founded by Marc Andreessen and Ben Horowitz. Vijay Pande is a The post Biotech Special: a16z and the Biotech Revolution with Vijay Pande appeared first on Software Engineering Daily.

In this episode, Joe Grogan, a senior fellow at the Leonard D. Schaeffer Center for Health Policy and Economics and a former senior government official, joins Vijay Pande, founding partner of a16z Bio + Health to discuss all things regulation.Together, they dive into Joe's experience working in the early days of the Covid pandemic, how he thinks about the Inflation Reduction Act's effect on pharmaceutical R&D, and the future of AI regulation.Additional reading:Check out Joe's latest op-ed here, his own podcast here, and his Twitter account here. 

Big news from a16z: Bio Eats World, our sibling show from a16z Bio+Health, is now Raising Health!We're excited to share Raising Health's first episode here where Sean Duffy, cofounder and CEO of Omada Health, joins Vijay Pande, founding general partner of Bio + Health.Sean and Vijay discuss the building and growth of Omada, from the early days to now. As the cofounder of one of the original digital health companies, Sean has unique insight into the growth of both the digital health field and the changing venture capital environment. They also talk about the future of AI, how Omada is leveraging AI, and the challenges that might arise with using a technology in a caregiving environment.You can listen to more episodes of Raising Health here: https://link.chtbl.com/IqBoJ2By?sid=a16z11824

Bio Eats World is now Raising Health!Vijay Pande, founding partner of Bio + Health, is joined by Daphne Koller, Andrew Ng, Aviv Regev, and Jakob Uszkoreit.Vijay leads us on a reflective journey through the monumental achievements in AI from the 1980s to today, with a focus on the progress in healthcare and life sciences. This episode is drawn from the episodes we recorded in 2023 with Daphne Koller, Andrew Ng, Aviv Regev, and Jakob Uszkoreit, which are linked below.This blend of expert commentary and firsthand insights explores the burgeoning impact of AI on healthcare innovation and how it's reshaping the future of health.AI and Actionable Insights for Drug Development with Daphne KollerNavigating the Future of AI with Andrew NgWhen Quantity Becomes Quality with Aviv RegevUsing AI to Take Bio Farther with Jakob Uszkoreit

Bio Eats World is now Raising Health!On this first episode of Raising Health, Sean Duffy, cofounder and CEO of Omada Health, joins Vijay Pande, founding partner of Bio + Health.Sean and Vijay discuss the building and growth of Omada, from the early days to now. As the cofounder of one of the original digital health companies, Sean has unique insight into the growth of both the digital health field and the changing venture capital environment.  They also talk about the future of AI, how Omada is leveraging AI, and the challenges that might arise with using a technology in a caregiving environment.

Welcome to “The Ben & Marc Show”, featuring a16z's co-founders Ben Horowitz and Marc Andreessen.  In this week's episode, Marc and Ben are joined by special guest Tony Robbins to discuss the future of longevity.  Tony Robbins is an entrepreneur, #1 NY Times bestselling author, philanthropist, and the nation's #1 life & business strategist.  For over four and a half decades, Tony has empowered more than 50 million people from 100 countries around the world through his audio programs, educational videos, and live seminars. He's also the author of six international bestsellers, including “Money: Master the Game” (2014), “Unshakable: Your Financial Freedom Playbook” (2017) and “Life Force: How New Breakthroughs in Precision Medicine Can Transform the Quality of Your Life and Those You Love” (2022).Joined by a16z's own Dr. Vijay Pande, PhD – General Partner since 2014, and founder and leader of a16z Bio + Health – the group discusses new breakthroughs in regenerative medicine, AI, biohacking, gene editing, mindset and confirms why this might be the best time to be alive. Enjoy!Watch the full video version of this episode: https://youtu.be/V8h11baC_ok Resources:Marc on X: https://twitter.com/pmarcaMarc's Substack: https://pmarca.substack.com/Ben on X: https://twitter.com/bhorowitzDr. Vijay Pande on X: https://twitter.com/vijaypandeLearn more about Tony Robbins: https://tonyrobbins.comTony's Time to Rise Summit (Jan 25-27, 2024): https://timetorisesummit.com/join-now  Pre-order Tony's upcoming book “The Holy Grail of Investing” (Feb 2024): http://theholygrailofinvesting.com Stay Updated: Find a16z on Twitter: https://twitter.com/a16zFind a16z on LinkedIn: https://www.linkedin.com/company/a16zSubscribe on your favorite podcast app: https://a16z.simplecast.com/Follow our host: https://twitter.com/stephsmithioPlease note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.

Welcome to “The Ben & Marc Show”, featuring a16z's co-founders Ben Horowitz and Marc Andreessen.  In this week's episode, Marc and Ben are joined by special guest Tony Robbins to discuss the future of longevity.   Tony Robbins is an entrepreneur, #1 NY Times bestselling author, philanthropist, and the nation's #1 life & business strategist.  For over four and a half decades, Tony has empowered more than 50 million people from 100 countries around the world through his audio programs, educational videos, and live seminars. He's also the author of six international bestsellers, including “Money: Master the Game” (2014), “Unshakable: Your Financial Freedom Playbook” (2017) and “Life Force: How New Breakthroughs in Precision Medicine Can Transform the Quality of Your Life and Those You Love” (2022). Joined by a16z's own Dr. Vijay Pande, PhD – General Partner since 2014, and founder and leader of a16z Bio + Health – the group discusses new breakthroughs in regenerative medicine, AI, biohacking, gene editing, mindset and confirms why this might be the best time to be alive. Enjoy! Watch the full video version of this episode: https://youtu.be/V8h11baC_ok Resources:Marc on X: https://twitter.com/pmarcaMarc's Substack: https://pmarca.substack.com/ Ben on X: https://twitter.com/bhorowitz Dr. Vijay Pande on X: https://twitter.com/vijaypande Learn more about Tony Robbins https://tonyrobbins.comTony's Time to Rise Summit (Jan 25-27, 2024): https://timetorisesummit.com/join-now  Pre-order Tony's upcoming book “The Holy Grail of Investing” (Feb 2024): http://theholygrailofinvesting.com Stay Updated: Find us on X: https://twitter.com/a16zFind us on LinkedIn: https://www.linkedin.com/company/a16z The views expressed here are those of the individual personnel quoted and are not the views of a16z or its affiliates. This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. Furthermore, this content is not directed at nor intended for use by any investors or prospective investors and may not under any circumstances be relied upon when making a decision to invest in any a16z funds. PLEASE SEE MORE HERE: https://a16z.com/disclosures/

Pranav Rajpurkar, PhD, joins Vijay Pande, founding partner of a16z Bio + Health.In this episode, Pranav and Vijay discuss a future with generalist medical AI. This is the idea of a medical AI that isn't narrowly tailored to one specific task. As Pranav notes in the episode, the research and development process in medical AI development so far has been siloed by specialty, but generalist medical AI exists outside those siloes. If generalist medical AI is successful, it could act as a dynamic support system to a physician, almost like a medical resident.

Miriam Vogel, President and CEO of EqualAI, cohost of the podcast In AI We Trust?, and Chair of the National AI Advisory Committee, joins Vijay Pande of Bio + Health.Miriam offers pragmatic insights for founders on ethical integration of AI. She also outlines concrete steps to build trustworthy AI. Finally, she discusses the regulatory landscape and the state of politics around AI today.

AI trailblazer Suchi Saria, in conversation with Vijay Pande, sheds light on the winding path that led her to launch Bayesian Health, a bold effort to infuse intelligence into clinical workflows. With infectious optimism, Suchi describes her vision to create "clinical copilots" that augment human capabilities and unburden care teams. Yet she acknowledges the delicate balancing act required to implement AI ethically, emphasizing the need for continuous monitoring and oversight to build trust. For founders navigating uncertain regulatory seas, Suchi offers a lifeline, suggesting that regulation done right may actually accelerate adoption by fostering confidence. Through candid reflections on lessons from the trenches, Suchi provides a rare glimpse into the mind of an innovator who has one foot planted in research rigor and the other striding towards real-world impact. Steeped in over 20 years of experience, her insights map guideposts for founders aspiring to positively disrupt healthcare with AI.

Fei-Fei Li, PhD,  Professor in the Computer Science Department at Stanford University, and Co-Director of Stanford's Human-Centered AI Institute, joins Bio + Health founding partner Vijay Pande.In this candid conversation, Li unfolds her transformation from a young immigrant to an influential figure in AI. The conversation explores the birth of ImageNet, a pivotal step that bridged the gap between visual intelligence and accessible AI technology. They delve into the notion of a 'Dignity Economy,' hinting at a future where technology serves to elevate human experience rather than undermine it. Li also touches on the delicate balance between relentless innovation and life's humble pursuits. This episode peels back the layers on the human side of AI, offering a rare glimpse into the personal and professional realms of a pioneer shaping the AI landscape.Check out her new book, The Worlds I See, here: https://us.macmillan.com/books/9781250897930/theworldsiseeCheck out other episodes form our sister podcast, Bio Eats World: https://a16z.com/podcasts/bio-eats-world/ Stay Updated: Find a16z on Twitter: https://twitter.com/a16zFind a16z on LinkedIn: https://www.linkedin.com/company/a16zSubscribe on your favorite podcast app: https://a16z.simplecast.com/Follow our host: https://twitter.com/stephsmithioPlease note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.

Fei-Fei Li, PhD,  Professor in the Computer Science Department at Stanford University, and Co-Director of Stanford's Human-Centered AI Institute, joins Bio + Health founding partner Vijay Pande.In this candid conversation, Li unfolds her transformation from a young immigrant to an influential figure in AI. The conversation explores the birth of ImageNet, a pivotal step that bridged the gap between visual intelligence and accessible AI technology. They delve into the notion of a 'Dignity Economy,' hinting at a future where technology serves to elevate human experience rather than undermine it. Li also touches on the delicate balance between relentless innovation and life's humble pursuits. This episode peels back the layers on the human side of AI, offering a rare glimpse into the personal and professional realms of a pioneer shaping the AI landscape.Check out her new book, out November 7, 2023, here: https://us.macmillan.com/books/9781250897930/theworldsisee

Evan Feinberg, PhD, founder and CEO at Genesis Therapeutics, joins Vijay Pande of Bio + Health.Together, they talk about how Evan's work in the lab (ironically, Vijay's lab at Stanford!) translated to the creation of Genesis, which is tackling the problem of drug discovery through AI. They also discuss how the Genesis team is building specifically to carry on work at the intersection of ML, biotech, and chemistry.

Olga Troyanskaya, a professor in the department of computer science at Princeton and Deputy Director for Genomics at the Flatiron Institute's Center for Computational Biology, joins Vijay Pande, founding partner of a16z Bio + Health.Together, they talked about Olga's background and how she got involved in genomics, as well as how evolving biotechnologies have improved scientists' ability to see different views of the cell. They also discussed social determinants of health, and how, in the future, studies of genomics and SDoH might pave the way to treatment options.

Note that due to technical difficulties, the audio quality of this episode may vary.Surya Ganguli, PhD, an associate professor at Stanford University and a neural dynamics researcher, joins Vijay Pande of Bio + Health.Together, Surya and Vijay chatted about the interpretability of AI and how the AI black box could someday become a "clear box." They also talk through a future of AI-augmented humans, and where humans might excel compared with AI. 

This episode is live from our recent AI Revolutionaries (AIR) conference. In this episode, Daphne Koller, founder and CEO at insitro and AI expert, chats with Vijay Pande of Bio + Health.You can check out the full conversation with video and transcript at https://a16z.com/digital-biology/. 

Today's episode features Aviv Regev, PhD, the Head and Executive VP of Genentech Research and Early Development, and founding co-chair of the Human Cell Atlas. She is joined by Vijay Pande of Bio + Health.Together, Aviv and Vijay talk about how Aviv's love of both abstractions and details led her to biology, how CRISPR really set the field into motion, and how AI could transform the process of biological and medical discovery.

Andrew Ng, PhD, a distinguished authority in the field of AI, is known for founding DeepLearning.AI and multiple other ventures. He also co-founded and led Google Brain and serves as an Adjunct Professor in Stanford University's Computer Science Department. In this episode, he is joined by Vijay Pande, founding partner of a16z Bio + Health.Andrew has thought deeply about the implications of integrating AI into many areas of our lives, going so far as to put out a public social media call for people who believe AI is dangerous to speak with him. He and Vijay discussed this, as well as how AI could become foundational to many industries — and what needs to happen to make that future a reality.

Today's episode is with Mark Cuban, founder of multiple businesses, owner of the Dallas Mavericks, one of the sharks on Shark Tank, and cofounder of the Mark Cuban Cost Plus Drug Company. He is joined by Vijay Pande, founding partner of a16z Bio + Health. Together, they talk market forces in healthcare, the importance of trust to patients, and Mark's ideas to tackle the Gordian knot that is American healthcare. Listen to our last two episodes on Healthcare x Fintech:When Two Giants Intersect: Healthcare Meets FintechHow Fintech is Reshaping Our $4T Healthcare Industry Stay Updated: Find a16z on Twitter: https://twitter.com/a16zFind a16z on LinkedIn: https://www.linkedin.com/company/a16zSubscribe on your favorite podcast app: https://a16z.simplecast.com/Follow our host: https://twitter.com/stephsmithioPlease note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.

AI is not just a sci-fi concept anymore; it's being woven into the fabric of healthcare, revolutionizing everything from research to patient care. It has the potential to create more streamlined and efficient processes. The challenge now is how we adapt and regulate this ever-evolving technology, while ensuring safety and trust.Amy Abernethy, former Principal Deputy Commissioner at the FDA and now the President of Product Development and Chief Medical Officer at Verily Life Sciences, joins Vijay Pande, founding partner of a16z Bio + Health, to discuss.

Today's episode is with Mark Cuban, founder of multiple businesses, owner of the Dallas Mavericks, one of the sharks on Shark Tank, and cofounder of the Mark Cuban Cost Plus Drug Company. He is joined by Vijay Pande, founding partner of a16z Bio + Health. Together, they talk market forces in healthcare, the importance of trust to patients, and Mark's ideas to tackle the Gordian knot that is American healthcare.

Today's episode is with Magi Richani, founder and CEO of Nobell Foods. She is joined by a16z Bio + Health general partner Vijay Pande.Together, they talk about the details of engineering plants to create the future of food, why Nobell started with soybeans to produce their cheese, and her dream of finding a cheese pizza—with Nobell cheese—at any pizza shop across the country.

The Sunday Times' tech correspondent Danny Fortson brings on Vijay Pande, head of Andreessen Horowitz's $1.5bn bio fund, to talk about how artificial intelligence is impacting healthcare (3:30), tools that “understand” biology (8:50), trying to eliminate cancer (12:50), trying to get techie founders to get into healthcare (14:25), America's plunging life expectancy (18:00), the (potential) end of radiology (21:10), AI's “hallucination" problem in healthcare (25:55), the future of therapy (29:00), putting healthcare on the Moore's Law curve (33:10), using automation to slash the industry's costs and inefficiencies (37:30), the next trillion dollar company (40:00), if capitalism is the best way to crack healthcare (45:40), and solving the billing problem(48:35). Hosted on Acast. See acast.com/privacy for more information.